When it comes to weight-loss jab could be made for $3 a month, study finds, new research indicates that the weight-loss injection semaglutide, marketed as Wegovy, could be produced for as little as $3 a month. This finding opens the door to affordable access for millions in low-income countries, especially as patents expire. With global obesity rates climbing rapidly, particularly in lower-income regions, this development could have a profound impact on public health.
Understanding Weight-loss Jab Could Be Made For $3 A Month, Study Finds
Today, more than a billion people worldwide are living with obesity, a figure that continues to rise sharply, especially in countries transitioning to Western dietary habits and increasingly sedentary lifestyles. The World Health Organization identified semaglutide as an essential medicine in September 2022, highlighting the urgent need for effective treatments amid escalating obesity rates. Originally reported by The Guardian.
Semaglutide, sold under the brand name Wegovy for obesity and Ozempic for diabetes, has been a game-changer in weight management. However, despite its effectiveness, the high cost-approximately $200 a month in the United States and ÂŁ120 in the UK-has limited its accessibility. The recent analysis, published as a pre-print, suggests that mass production could bring the cost down to $3 (around ÂŁ2.35) for a month's supply of the injectable form. For the newer oral formulations, the estimated monthly cost would be about $16.
Patent Expiry and Global Access
Significantly, the research points out that core patents for semaglutide will expire this year in ten countries, including Brazil, China, India, South Africa, Turkey, Mexico, and Canada, starting from March 21. This opens the door to generic competition, which could drastically lower prices and increase availability in these regions. The researchers also identified 150 countries where patents have not yet been filed, many of which are in Africa. These 160 countries collectively house 69% of individuals with type 2 diabetes and 84% of those living with obesity.
Dr. Andrew Hill from Liverpool University, one of the study's authors, stated, "These low prices open the door to worldwide access to an essential medicine." His sentiments reflect a broader hope that this significant reduction in cost could lead to improved health outcomes for millions who currently lack access to effective weight management treatments.
Challenges Beyond Medication Availability
While the potential for affordable weight-loss jabs is promising, researchers caution that simply providing these medications won't tackle the underlying causes of obesity. Issues like food insecurity, poverty, urbanization, and the prevalence of unhealthy food environments are interconnected factors that need addressing through coordinated policies and health initiatives. Dr. Nomathemba Chandiwana, chief scientific officer at South Africa's Desmond Tutu Health Foundation, emphasized that while lower prices could significantly benefit countries like South Africa, the integration of these drugs into broader healthcare strategies is critical.
Chandiwana noted that about 27% of adults globally meet the criteria for treatments such as semaglutide, with the majority living in low and middle-income countries where access remains limited. Her insights highlight the importance of creating a comprehensive approach to obesity and diabetes care that includes education, prevention, and treatment.
A Broader Impact on Global Health
Obesity is not just a standalone issue; it contributes to a range of serious health conditions, including heart disease, diabetes, stroke, and cancer. Each year, excess weight is linked to approximately 3.7 million deaths globally. The rise of diabetes is particularly alarming, with the number of people living with the condition soaring from 200 million in 1990 to 830 million in 2022, predominantly in low- and middle-income countries.
Since its approval by US regulators in 2017, semaglutide has shown significant promise in weight loss and diabetes management. However, for many, the financial barrier remains a critical challenge. While patents in the UK, continental Europe, and the US will not expire for another five years, the recent findings indicate a pathway toward more equitable access in the near future.
As the healthcare community continues to address the obesity epidemic, the prospect of affordable weight-loss jabs like semaglutide could represent a turning point in treatment accessibility and health equity across the globe.
Originally reported by The Guardian. View original.